Bexarotene (Targretin) for cutaneous T-cell lymphoma.
D000077610:Bexarotene; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D005252:Fees, Pharmaceutical; D006207:Half-Life; D006801:Humans; D015228:Hypertriglyceridemia / Q000139:chemically induced; D007037:Hypothyroidism / Q000139:chemically induced; D016410:Lymphoma, T-Cell, Cutaneous / Q000188:drug therapy*; D018168:Receptors, Retinoic Acid / Q000378:metabolism; D012176:Retinoids; D013764:Tetrahydronaphthalenes / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*
D018168:Receptors, Retinoic Acid; D012176:Retinoids; D013764:Tetrahydronaphthalenes; D000077610:Bexarotene